AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
Theriva Biologics shares rise 15.02% intraday after EMA approves VCN-01 Phase 3 trial design.
ByAinvest
Friday, Jan 2, 2026 12:36 pm ET1min read
Theriva Biologics surged 15.02% intraday following European Medicines Agency (EMA) approval for its Phase 3 trial design of VCN-01 in combination with gemcitabine/nab-paclitaxel for metastatic pancreatic cancer. The regulatory milestone validates the therapy’s potential to improve patient outcomes and secures funding for trials through 2027, bolstering investor confidence in the company’s oncology platform. While pre-market trading saw a 5.28% decline amid broader sector rotation, the intraday rebound reflects renewed optimism about the drug’s development trajectory and Theriva’s competitive positioning in the cancer treatment market.
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc's editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet